Travere Therapeutics Inc
TVTXHealthcare|Biotechnology|USA
$56.60
-1.88 (-3.22%)
About
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Stock Price
+242.0%(1Y)
Pipeline Summary
19 total trials3
Phase 1
6
Phase 2
5
Phase 3
1
Phase 4
Active: 4Recruiting: 4Completed: 7Terminated: 1NOT_YET_RECRUITING: 1ENROLLING_BY_INVITATION: 2
Active Trials (8)
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
NCT07219121Proteinuria
Phase 4Active
Enrollment: 20 participants
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
NCT04663204Immunoglobulin A Nephropathy
Phase 2Recruiting
Enrollment: 24 participants
Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)
NCT03406611Homocystinuria
Phase 1Phase 2Active
Enrollment: 32 participants
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
NCT06247085Homocystinuria
Phase 3Recruiting
Enrollment: 70 participants
Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA)
NCT02998710Homocystinuria Due to CBS Deficiency
Recruiting
Enrollment: 150 participants
BioScore
5.4/10
Watchlist
Ownership
Recent Insider Trades
Coughlin TimothySELL
2026-06-1210,000 shares @ $50.07
Baynes Roy D.SELL
2026-06-124,500 shares @ $50
Coughlin TimothySELL
2026-05-153,250 shares @ $43.49
ROTE WILLIAM E.SELL
2026-05-062,763 shares @ $43.95
REED ELIZABETH ESELL
2026-05-0624,250 shares @ $45.06
Recent News
2026-07-10 21:00:07
2026-06-25 14:42:38
2026-06-22 13:33:58
2026-06-18 16:05:18
2026-06-16 21:00:13
Data last updated: Jul 12, 2026, 07:37 PM